Pharmaceutical company Mylan NV (NASDAQ:MYL) and Fujifilm Kyowa Kirin Biologics Co Ltd on Thursday jointly announced US Food and Drug Administration (FDA) approval for Hulio (adalimumab-fkjp) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis (4 years and older), psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.
Hulio, a biosimilar to AbbVie's Humira (adalimumab), was approved in both prefilled syringe and auto-injector presentations.
Humira had brand sales of approximately USD14.9bn in the US for the 12 months ending December 2019.
Under a patent licence agreement with AbbVie, Mylan will be able to launch Hulio in the US in July 2023.
The FDA approval of Hulio was based on a comprehensive analytical, preclinical and clinical programme. The Phase 3 clinical study ARABESC, conducted by Fujifilm Kyowa Kirin Biologics, demonstrated no clinically meaningful differences in terms of safety, efficacy and immunogenicity compared with the reference product, Humira, in rheumatoid arthritis patients.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients